Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
GLP-1 therapy helps shift this pattern
While you can't get a Retatrutide prescription today, knowing its potential impact is important as you explore options in medical weight loss in Wausau
Acta (BBA) - Gen
GLP-1 (1) , ,
US$ 28.89
US$ 25.14
US$ 29.58
US$ 21.98
